<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="51162">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02440152</url>
  </required_header>
  <id_info>
    <org_study_id>2014-15</org_study_id>
    <nct_id>NCT02440152</nct_id>
  </id_info>
  <brief_title>The Effectiveness of Deep Brain Stimulation for Opioid Relapse Prevention</brief_title>
  <official_title>The Effectiveness of Deep Brain Stimulation for Opioid Relapse Prevention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Suzhou Sceneray Medical Co. , Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institution of Neuroscience</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Natural Science Foundation of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The nucleus accumbens (NAcc) has a significant role in the process of opiate addiction and
      the initiation of relapse after detoxification. There is evidence that deep brain
      stimulation (DBS) of the NAcc exerts a positive effect on individuals with severe heroin
      addiction via inhibitory action .

      The investigators hypothesise that bilateral stimulation of the NAcc will significantly
      reduce withdrawal symptoms and thus enable the patients to substantially decrease their
      Levomethadone usage.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of Levomethadone</measure>
    <time_frame>Baseline (preoperative), 3 months, 6 months, 9 months, 12 months, 18 months, 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in 10-point visual analog scale (VAS) craving score for opioid drugs</measure>
    <time_frame>Baseline (preoperative), 3 months, 6 months, 9 months, 12 months, 18 months, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Addiction Severity Index (ASI) lite score</measure>
    <time_frame>Baseline (preoperative), 3 months, 6 months, 9 months, 12 months, 18 months, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hamilton Anxiety Scale</measure>
    <time_frame>Baseline (preoperative), 3 months, 6 months, 9 months, 12 months, 18 months, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hamilton Depression Scale-17</measure>
    <time_frame>Baseline (preoperative), 3 months, 6 months, 9 months, 12 months, 18 months, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Temperament and Character Inventory</measure>
    <time_frame>Baseline (preoperative), 6 months, 12 months, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in WHO disability assessment 2.0, self, 12terms</measure>
    <time_frame>Baseline (preoperative), 6 months, 12 month, 24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in dopamine transporter positron emission tomography (PET) brain metabolism images</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Dopamine transporter (DAT) will be utilized to evaluate cerebral metabolism at each time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological measures（Scores of Iowa gambling task and Model task）</measure>
    <time_frame>Baseline (preoperative), Intraoperative,6 months,12month,24month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in (Chinese) Personality Assessment Inventory (CPAI-2) scores</measure>
    <time_frame>Baseline (preoperative), 6 months,12 months, 24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Global Assessment Function (GAF) scores</measure>
    <time_frame>Baseline (preoperative), 6 months, 12 months, 24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in eating and sexual activity: interview</measure>
    <time_frame>Baseline (preoperative), 6 months, 12 month, 24 month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Opiate Addiction</condition>
  <arm_group>
    <arm_group_label>Deep brain stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Suzhou Sceneray® DBS System</intervention_name>
    <arm_group_label>Deep brain stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Proficiency in Mandarin language

          -  Long lasting heroin addiction (determined by diagnostic-criteria in Diagnostic and
             Statistical Manual of Mental Disorders, Fifth Edition)

          -  Duration longer than 6 months

          -  A lack of response to long-term treatment

          -  Capacity to provide informed consent (understanding of the study purpose and methods)

          -  Substitution methadone treatment at a constant dose within three months prior to
             inclusion.

        Exclusion Criteria:

          -  Clinical relevant psychiatric comorbidity (schizophrenic psychoses, bipolar affective
             diseases with psychotic symptoms)(MINI 6.0)

          -  Past stereotactic neurosurgical intervention

          -  Neurological disease (Abnormal PET-CT, MRI, EEG)

          -  Contraindications of MRI-examination, e.g. implanted cardiac pacemaker/ heart
             defibrillator

          -  Contraindications of stereotactic intervention, e.g. increased bleeding-disposition,
             cerebrovascular diseases (e.g. arteriovenous malfunction, aneurysms, systemic
             vascular diseases)

          -  Serious and unstable organic diseases (e.g. unstable coronal heart disease)

          -  HIV positive

          -  Pregnancy and/or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bomin Sun, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ChenCheng Zhang, MD</last_name>
    <email>i@cczhang.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristina Zeljic, MSc</last_name>
    <email>zeljickristina@ion.ac.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai RuiJin Hospital Psychitric Department</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haiyan Jin, MD</last_name>
      <email>hyjin603@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Mental Health Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiang Du, MD</last_name>
      <email>dujiangdou@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Min Zhao, MD,PhD</last_name>
      <email>drzhaomin@sh163.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Luigjes J, van den Brink W, Feenstra M, van den Munckhof P, Schuurman PR, Schippers R, Mazaheri A, De Vries TJ, Denys D. Deep brain stimulation in addiction: a review of potential brain targets. Mol Psychiatry. 2012 Jun;17(6):572-83. doi: 10.1038/mp.2011.114. Epub 2011 Sep 20. Review.</citation>
    <PMID>21931318</PMID>
  </reference>
  <results_reference>
    <citation>Kuhn J, Möller M, Treppmann JF, Bartsch C, Lenartz D, Gruendler TO, Maarouf M, Brosig A, Barnikol UB, Klosterkötter J, Sturm V. Deep brain stimulation of the nucleus accumbens and its usefulness in severe opioid addiction. Mol Psychiatry. 2014 Feb;19(2):145-6. doi: 10.1038/mp.2012.196. Epub 2013 Jan 22.</citation>
    <PMID>23337942</PMID>
  </results_reference>
  <results_reference>
    <citation>Valencia-Alfonso CE, Luigjes J, Smolders R, Cohen MX, Levar N, Mazaheri A, van den Munckhof P, Schuurman PR, van den Brink W, Denys D. Effective deep brain stimulation in heroin addiction: a case report with complementary intracranial electroencephalogram. Biol Psychiatry. 2012 Apr 15;71(8):e35-7. doi: 10.1016/j.biopsych.2011.12.013. Epub 2012 Jan 26.</citation>
    <PMID>22281120</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhou H, Xu J, Jiang J. Deep brain stimulation of nucleus accumbens on heroin-seeking behaviors: a case report. Biol Psychiatry. 2011 Jun 1;69(11):e41-2. doi: 10.1016/j.biopsych.2011.02.012. Epub 2011 Apr 13.</citation>
    <PMID>21489407</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 14, 2016</lastchanged_date>
  <firstreceived_date>March 29, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Bomin Sun</investigator_full_name>
    <investigator_title>Department of Functional Neurosurgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
